Verana Health announced that it has acquired the assets of data science company PYA Analytics (PYAA). Based in Knoxville, Tennessee, PYAA specializes in large-scale data architecture solutions.
Terms of the deal were not disclosed.
PYAA was founded in 2013 by scientists and engineers from nearby Oak Ridge National Laboratory, the largest multi-program science, and technology laboratory in the United States. Members of PYAA have led projects that include the linking of clinical records with images to improve early detection, the utilization of satellite images with other data sources to inform geospatial analysis, and early members of the Human Genome Project. The data scientists, engineers, and data architects joining through the acquisition will diversify and expand the scope of Verana’s capabilities, according to a company news release.
“PYA Analytics is a data science company that develops state-of-the-art products for data linking and analysis,” Dr. Brian Worley, Co-founder and CEO of PYA Analytics, said in the news release. “We are thrilled to join Verana to enrich these extraordinary clinical databases and find answers to some of the most pressing challenges in medicine.”
The PYAA team will remain in Knoxville, and Verana plans to hire and grow the office in the coming months. The company also intends to further scale its San Francisco headquarters and New York office in the coming year.
Verana Health also announced the close of a $100 million investment led by GV (formerly Google Ventures). New investors Bain Capital Ventures, Casdin Capital, and Define Ventures also participated in the round along with the company’s existing slate of investors.
“Verana Health is building the team and technology to unlock deep clinical insights that support the development of new treatments while increasing our understanding of how these treatments can benefit patients more broadly,” Dr. Krishna Yeshwant, General Partner at GV, said in a company news release. “Under the leadership of its strong management team, Verana continues to redefine how we approach medical research.”
Verana’s platform aggregates regulatory-grade datasets through its partnership with two of the largest clinical databases in medicine, the American Academy of Ophthalmology (AAO) IRIS Registry, and the American Academy of Neurology (AAN) Axon Registry. The company curates and analyzes this de-identified EHR-derived data to advance medical research and patient care in the areas of ophthalmic and neurologic diseases. Verana plans to expand into additional therapeutic categories over the next year as well as integrate imaging, genomic, and claims data sources.
“Verana is assembling the most comprehensive datasets in medicine across multiple disease types with the goal of accelerating medical research for patients with ophthalmic and neurologic conditions,” said Miki Kapoor, CEO of the Verana Health. “The financing and the addition of PYAA enable us to enrich these large clinical databases, creating a longitudinal view of the complete patient journey to inform research and patient care.”